CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On- and Off-Label Criteria
Jörg Carlsson, MD, PhD*,*,
Stefan K. James, MD, PhD ,
Johan Lindbäck, PhD,
Fredrik Scherstén, MD, PhD ,
Tage Nilsson, MD, PhD,
Ulf Stenestrand, MD, PhD ,
Bo Lagerqvist, MD, PhD for the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) Study Group
* Department of Internal Medicine, Division of Cardiology, Kalmar County Hospital, Kalmar, Sweden
Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
Department of Cardiology, Helsingborg Hospital, Helsingborg, Sweden
Department of Cardiology, Linköping University Hospital, Linköping, Sweden
Manuscript received June 5, 2008;
revised manuscript received August 8, 2008,
accepted September 18, 2008.
* Reprint requests and correspondence: Dr. Jörg Carlsson, Länssjukhuset i Kalmar, Lasarettsvägen, S-39185 Kalmar, Sweden (Email: jorgc{at}ltkalmar.se).
Objectives: The aim of this study was to investigate the outcome of bare-metal stents (BMS) versus drug-eluting stents (DES) after on-label as well as off-label use.
Background: DES lower restenosis rates while not influencing the risk for death and myocardial infarction when used in Federal Food and Drug Administration (FDA)-approved indications. It is debated whether the clinical results of this so-called on-label use might be extrapolated to off-label situations.
Methods: The SCAAR (Swedish Coronary Angiography and Angioplasty Registry) was used to investigate the outcomes in 17,198 patients who underwent stenting with an on-label indication (10,431 BMS and 6,767 DES patients) and 16,355 patients in the context of an off-label indication (9,907 BMS and 6,448 DES patients). The patients were included from 2003 to 2005 with a minimum follow-up of 1 year and a maximum of 4 years. The analysis was adjusted for differences in baseline characteristics.
Results: There were not significant differences between on-label DES and BMS (adjusted hazard ratio: 1.02; 95% confidence interval: 0.92 to 1.13) or between off-label DES and BMS (adjusted hazard ratio: 0.95; 95% confidence interval: 0.87 to 1.04) use with regard to the incidence of myocardial infarction and death. Off-label use of DES did not lead to significant differences in the combined risk of death and myocardial infarction compared with BMS throughout the whole spectrum of clinical indications.
Conclusions: In contemporary Swedish practice, neither on- nor off-label use of DES is associated with worse outcome than use of BMS.
Key Words: BMS • DES • off-label • on-label • outcome
|
Abbreviations and Acronyms
| | BMS = bare-metal stent(s) | | CABG = coronary artery bypass graft | | CAD = coronary artery disease | | CI = confidence interval | | DES = drug-eluting stent(s) | | IQR = interquartile range | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | RR = relative risk | | SES = sirolimus-eluting stent(s) | | STEMI = ST-segment elevation myocardial infarction |
|
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A30.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
G. Sarno, B. Lagerqvist, O. Frobert, J. Nilsson, G. Olivecrona, E. Omerovic, N. Saleh, D. Venetzanos, and S. James
Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Eur. Heart J.,
January 9, 2012;
(2012)
ehr479v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Stefanini, P. W. Serruys, S. Silber, A. A. Khattab, R. J. van Geuns, G. Richardt, P. E. Buszman, H. Kelbaek, A. J. van Boven, S. H. Hofma, et al.
The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents: A Substudy of the RESOLUTE All Comers Trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention)
J. Am. Coll. Cardiol.,
May 31, 2011;
57(22):
2221 - 2232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Jernberg, M. F. Attebring, K. Hambraeus, T. Ivert, S. James, A. Jeppsson, B. Lagerqvist, B. Lindahl, U. Stenestrand, and L. Wallentin
The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)
Heart,
October 15, 2010;
96(20):
1617 - 1621.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
May 18, 2010;
55(20):
2272 - 2286.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Colmenarez, J. Escaned, C. Fernandez, L. Lobo, S. Cano, J. G. del Angel, F. Alfonso, P. Jimenez, C. Banuelos, N. Gonzalo, et al.
Efficacy and Safety of Drug-Eluting Stents in Chronic Total Coronary Occlusion Recanalization: A Systematic Review and Meta-Analysis
J. Am. Coll. Cardiol.,
April 27, 2010;
55(17):
1854 - 1866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol.,
January 26, 2010;
55(4):
380 - 407.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Drachman
Drug-Eluting Stents in Animals and Patients: Where Do We Stand Today?
Circulation,
July 14, 2009;
120(2):
101 - 103.
[Full Text]
[PDF]
|
|
|
|
